Prostate cancer is the first most common cancer in men worldwide. In Luxembourg, each year 350 new cases are diagnosed, it mainly affects men over 50 years.
Once prostate cancer becomes metastatic, the survival of the patient depend on the extent of the disease and the site of metastases. In more than 90% of the castration-resistant prostate cancer, the most common site of metastases is the skeletal system.
The aim of the observational study REASSURE is to evaluate the safety profile of Radium 223 Dichloride (Xofigo®), a radiopharmaceutical on the market since November 2013. Xofigo® selectively targets bone metastases. It mimics calcium and forms complexes with the bone mineral at sites of bone metastases. It then emits alpha particles, causing the destruction of DNA in nearby cells, resulting in cancer cell death in the bone. Xofigo® is used when patients became castration resistant and when the cancer has spread to the bones and is causing symptoms such as pain.
Luxembourg participates with two sites, Centre Hospitalier de Luxembourg (CHL) and the Centre Hospitalier Emile Mayrisch (CHEM) among 21 countries in the REASSURE study. CIEC-LIH supports the physicians participating in this study. In total it is planned to enrol 1334 patients. The study population will consist on patients with Castration Resistant Prostate Cancer (CRPC) who are treated with Xofigo®.
More information about this study here: www.luxclin.lu/Studies/Details/?c=STP3332BOW
for articles/videos/studies
Healthcare professionals who wish to be part of a unique network, providing access to up-to-date, accurate and validated information about clinical research.
Investigators and study staff who wish to be part of a unique network, in order to stay abreast of clinical trials taking place in Luxembourg and who are willing to further develop their competencies.
